Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02207946 · ClinicalTrials.gov registry record · Phase 2
Botulinum Toxin A to Treat Arm Tremor
A Phase 2 study, sponsored by Merz Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT02207946 is a Phase 2 study that has completed, run by Merz Pharmaceuticals. The registered enrollment target is 30 participants.
The verdict
NCT02207946, a Phase 2 study, has completed, sponsored by Merz Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
The objective of this study is to assess the efficacy and safety of a single, kinematic-analysis-based intramuscular injection of NT 201, compared with placebo, in moderate to marked essential tremor of the upper limb.
Interventions
- DRUG Placebo
- DRUG IncobotulinumtoxinA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2014-12-05 |
| Est. Completion | 2016-09-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02207946
The ClinicalTrials.gov registry entry for NCT02207946 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merz Pharmaceuticals, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02207946 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02207946 about?
NCT02207946 is a clinical study titled "Botulinum Toxin A to Treat Arm Tremor". The objective of this study is to assess the efficacy and safety of a single, kinematic-analysis-based intramuscular injection of NT 201, compared with placebo, in moderate to marked essential tremor of the upper limb.
What is the current status of trial NCT02207946?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2014-12-05. Estimated completion is 2016-09-26.
What interventions are being tested in trial NCT02207946?
The interventions under investigation include: Placebo (DRUG), IncobotulinumtoxinA (DRUG).
Who is sponsoring clinical trial NCT02207946?
This trial is sponsored by Merz Pharmaceuticals, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.